Posted by Michael Wonder on 25 Jan 2017
Atlantic Healthcare receives FDA agreement to initiate rolling submission of its new drug application for alicaforsen in the treatment of pouchitis
24 January 2017 - FDA to accept sections of the regulatory application ahead of final Phase 3 data expected in the second half of 2017
Atlantic Healthcare announces that it has received agreement from the U.S. FDA to initiate a rolling submission of its new drug application for alicaforsen to treat pouchitis, a serious form of inflammatory bowel disease that has limited treatment options.
